Article Archive

Page 51 of 55 · 2595 patient-friendly summaries

Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years
finance.yahoo.com

Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years

This press release reports multi-year clinical trial data suggesting sustained remission and intestinal healing with Omvoh (mirikizumab) in patients with Crohn's disease—information that could affect treatment...

Read Summary